R
RPRX
Royalty Pharma Plc
47.90
-0.40-0.83%After Hours: 48.05 +0.15 +0.31%18:29 04/10 EDT
OPEN/PREV CLOSE48.30/48.30
TODAY RANGE47.73-48.36
VOL2.37M
MARKET CAP27.63B
52 WEEK RANGE28.97-49.06
AVG VOL (3M)3.58M
% TURNOVER0.41%
TURNOVER--
P/E (TTM)26.89
% RANGE1.27%
EPS(TTM)1.781
P/E(FORWARD)13.76
P/B4.268
BVPS11.22
DIVIDEND0.9400
P/S11.62
BETA--
DIV YIELD1.96%
FREE FLOAT MKT CAP18.97B
SHARES OUTSTANDING576.86M
NEXT EARNINGS05/06-05/11
FREE FLOAT396.11M
LOT SIZE1
EX-DATE02/20/2026
News
Press Releases
Financial Reports
Profile
Reuters·18h ago
Royalty Pharma announces annual shareholder meeting
TipRanks·1d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
Simply Wall St·2d ago
Assessing Royalty Pharma (RPRX) Valuation After Johnson & Johnson Autoimmune Co Funding Deal
Simply Wall St·3d ago
Does J&J Co-Funding Deal Around Dual-Pathway Autoimmune Candidate Recast The Bull Case For Royalty Pharma (RPRX)?
Simply Wall St·6d ago
Royalty Pharma Leans Into R&D And AI To Shape Future Royalties
Reuters·04/02 21:59
Royalty Pharma CFO Terrance Coyne reports $1.7 million Class A share sale
Reuters·04/01 10:38
BUZZ-Zymeworks rises after naming new CFO
Reuters·04/01 10:00
Zymeworks appoints Kristin Stafford as CFO effective April 1, 2026
Reuters·03/30 12:58
Royalty Pharma and J&J partner to develop autoimmune treatment
Dow Jones·03/30 12:23
Royalty Pharma, Johnson & Johnson in $500 Million Autoimmune Drug Funding Pact
Seeking Alpha·03/30 11:45
Royalty Pharma in $500M R&D funding collaboration with J&J
Same Industry